Current Report Filing (8-k)
May 09 2016 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2016
ONCOTHYREON INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33882
|
|
26-0868560
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
(206) 801-2100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition
|
On May 9, 2016, Oncothyreon Inc.
(the Company) issued a press release regarding the Companys financial results for the quarter ended March 31, 2016. A copy of the Companys press release is attached hereto as Exhibit 99.1.
The information furnished with this report, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the
Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release issued by Oncothyreon Inc. dated May 9, 2016.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
ONCOTHYREON INC.
|
|
|
By:
|
|
/s/ Scott D. Myers
|
|
|
Scott D. Myers
|
|
|
President & Chief Executive Officer
|
Date: May 9, 2016
3
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release issued by Oncothyreon Inc. dated May 9, 2016.
|
4
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024